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Abstract: Currently, the world suffers from a new coronavirus SARS-CoV-2 that causes COVID-19. Therefore, there is a need for the
urgent development of novel drugs and vaccines for COVID-19. Since it can take years to develop new drugs against this disease, here
we used a hybrid combined molecular modeling approach in virtual drug screening repurposing study to identify new compounds
against this disease. One of the important SARS-CoV-2 targets namely type 2 transmembrane serine protease (TMPRSS2) was screened
with NPC’s NIH small molecule library which includes approved drugs by FDA and compounds in clinical investigation. We used
6654 small molecules in molecular docking and top-50 docking scored compounds were initially used in short (10-ns) molecular
dynamics (MD) simulations. Based on average MM/GBSA binding free energy results, long (100-ns) MD simulations were employed
for the identified hits. Both binding energy results as well as crucial residues in ligand binding were also compared with a positive
control TMPRSS2 inhibitor, Camostat mesylate. Based on these numerical calculations we proposed a compound (benzquercin) as
strong TMPRSS2 inhibitor. If these results can be validated by in vitro and in vivo studies, benzquercin can be considered to be used as
inhibitor of TMPRSS2 at the clinical studies.
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1. Introduction
Coronaviruses (CoVs) belong to a single-stranded RNA
(positive-sense) virus family which is encapsulated by a
membrane envelope (Durdagi et al., 2020). There are 4
common types of coronavirus (alpha, beta, gamma, and
delta) and cause mild upper respiratory tract diseases
(McKee et al., 2020). Human beta-coronaviruses are highly
pathogenic (Zhang et al., 2020). The SARS (Severe Acute
Respiratory Syndrome)-CoV was appeared in Guangdong
in China and infected 8096 people worldwide in 2002–
2003. The fatality rate was around 10% (i.e. 774 deaths).
In 2012, the MERS (Middle East Respiratory Syndrome)CoV infected about 2500 people and the fatality rate was
36% (Blanco-Melo et al., 2020). Currently, the world suffers
from a novel coronavirus SARS-CoV-2 that causes 2019
coronavirus disease (COVID-19). Like SARS and MERSCoVs, SARS-CoV-2 mainly affects the lower respiratory
tract (Blanco-Melo et al., 2020). It is characterized by a
number of symptoms such as fever, cough, diarrhoea,
and general weakness (Blanco-Melo et al., 2020). In
more serious cases, it causes acute respiratory distress
syndrome and lung damage leading to inflammation
and pneumonia. On the 11th of March 2020, the WHO

declared the COVID-19 as a pandemic (Hoffmann et
al., 2020). It affected the lives of hundreds of millions of
people as a result of compulsory isolation and quarantines
in the world (Sanders et al., 2020). SARS-CoV-2 targets
host cells via Spike protein that binds to the angiotensinconverting enzyme 2 (ACE2) receptor. The virus then
uses host cell receptors (i.e. type 2 transmembrane serine
protease (TMPRSS2)) and endosomes to enter the cells.
TMPRSS2 facilitates cell entry of SARS-CoV-2 through
the Spike protein. After entering the host cell, viral
proteins are synthesized that encode for the replicasetranscriptase complex (Mousavizadeh and Ghasemi 2020).
Viral RNA was then synthesized by RNA-dependent RNA
polymerase (Durdagi et al., 2020). The genome of SARSCoV-2 encodes for different structural and nonstructural
proteins (Sanders et al., 2020). The important ones for
drug development studies are Main Protease, and RNAdependent RNA polymerase (Cao et al., 2020). Currently
these proteins are mainly targeted for drug screening and
drug repurposing studies.
It is noteworthy that the method known as drug
repurposing has become less costly in terms of both time
and resources. In our laboratory, the use of molecules
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in different indications has been investigated with the
studies we have done in this field in recent years (Durdagi
et al., 2018; Is et al.,2018; Tutumlu et al., 2020). Since
the most of the preclinic and clinical studies including
pharmacokinetic and toxicological studies of approved
or compounds in clinical investigation phases have been
already tested, they require less time to make them suitable
for new indications. The toxicity and ADME (absorption,
distribution, metabolism and excretion) studies which
need long time to complete are not required as the
molecules considered in drug repositioning pass these
stages already that should be applied before and have welldefined profiles. Therefore, their use in epidemics is more
suitable than new molecules that have never been tested.
Hence, in the current study we performed a virtual drug
repurposing study. The small molecules from NCGC-NIH
Chemical Genomics Center Pharmaceutical Collection
(i.e. NPC library) were used in virtual screening studies
at the active site of developed TMPRSS2 model target
protein.
2. Materials and methods
We downloaded and prepared 7922 small compounds
from NPC library (https://tripod.nih.gov/npc/). Before
the virtual screening, to remove nonspecific compounds,
we performed some filtration criteria. Such as molecular
weights of compounds which are more than 1000 g/
mol and smaller than 100 g/mol were removed from
the library. The compounds that have more than 100
rotatable bonds or hydrogen bond acceptor and donor
number that is higher than 10 were also removed. Thus,
the total number of molecules were decreased to 6654
before the docking simulations. These compounds were
prepared with LigPrep module (LigPrep, Schrodinger
v.2017) of Maestro molecular modeling package. Since
the crystal structure of the TMPRSS2 was not available,
we performed homology modeling study. Swiss Model
was used in homology modeling study (swissmodel.
expasy.org). The 5CE1 PBB coded serine protease hepsin
was used as template structure. Sequence identity between
template and target proteins was 35.2%. Structural
assessment studies on the developed model have been
performed. There was no residue at the unfavourable
region at the Ramachandran’s plot and protein reports
showed no steric clashes, bond length or bond angle
deviations at the structure, thus it was suitable to use as
target protein (Supplementary Materials, Figure S1).
Before the docking, modelled target protein was prepared
using Protein Preparation module of Maestro molecular
modeling package. In the determination of protonation
states of residues at the target protein, PROPKA was used.
A restrained optimization protocol was employed with

186

OPLS3e force field for the target protein model using 0.3
Å convergence criteria. Docking was implemented with
Standard Precision (SP) protocol of Glide using default
settings. For the top-50 docking poses all-atom molecular
dynamics (MD) simulations were performed to mimic
physiological conditions using Desmond. Orthorhombic
box was used with explicit water models (i.e. TIP3P) that
have 10 Å thickness from the edges of the protein. 0.15
M NaCl was added to the simulation box to neutralize
the system. The particle mesh Ewald method was used
for long range electrostatic interactions. 9.0 Å cut-off was
used for both electrostatic and van der Waals interactions.
The temperature (310 K) and pressure (1.01325 bar)
throughout the simulations were kept constant by
Nose-Hoover thermostat (Evans and Holian, 1985) and
Martyna-Tobias-Klein barostat (Martyna et al., 1994).
The OPLS3e force field was used in MD simulations. 1000
trajectory frames for each system during the simulations
were collected. Molecular Mechanics Generalized Born
Surface Area (MM/GBSA) method was then employed for
these trajectories and average MM/GBSA score for each
studied compound was computed. The VSGB 2.0 solvation
model in Prime module of Maestro was employed in MM/
GBSA calculations.
3. Results and discussion
Nowadays thanks to the effort of NIH Chemical Genomics
Center, it is possible to obtain electronic resources of
collections of small molecules that have been registered.
Combining this with the power of recent advances of
ligand- and target-driven based virtual screening methods,
it has been made easier to consider drug repurposing
for any disease especially for complex diseases. We used
homology model target TMPRSS2 structure and screened
the prepared 6654 FDA approved drugs and compounds
in clinical investigation phases from NPC database using
Glide/SP. Docking scores were between –8.445 and 3.438
kcal/mol (Figure S2). Due to the limited flexibility of both
the target protein and the screened ligands in docking,
the identification of the compounds based on only
docking scores in docking simulations can lead to falsepositive results (Tutumlu et al., 2020). Moreover, although
molecular docking simulations may provide an insight into
protein/screened ligand interactions, it is always important
to understand how these interactions are sustained
throughout the performing MD simulations. Thus, we used
top-50 docking scored compounds and employed initially
short (10-ns) all-atom MD simulations in physiological
and body temperature conditions. Docking scores of top
50 compounds were between –8.445 and –6.962 kcal/mol
(see Figure 1 and Table at the Supplementary Materials).
An in-house script was used to prepare simulation boxes

DURDAĞI / Turk J Biol

Figure 1. Docking scores of top-50 screened compounds from
NPC database using Glide/SP.
Table. Docking scores of top-50 compounds at the TMPRSS2 binding site. These compounds were initially used in short (10-ns) MD
simulations. Table also shows average MM/GBSA scores of these compounds from derived 1000-trajectories throughout the simulations.

Reproterol

Docking score Average MM/GBSA
(kcal/mol)
(kcal/mol)
–8.445
–47.283

Ociltide

–8.204

–57.549

Theodrenaline

–8.120

–26.242

Hexafluronium bromide

–8.045

–67.775

Cliropamine

–8.028

–38.601

Dab-452

–7.912

–60.818

Fenoterol

–7.839

–45.418

Frakefamide

–7.785

–42.928

mitoxantrone

–7.749

–44.749

Adimolol

–7.677

–58.356

Mesuprina

–7.649

–45.323

Esorubicin

–7.549

–42.773

Arbutamine

–7.515

–56.584

Penimepicycline
(Alpha.s)-alpha-[alpha-(2,4-dimethyl-9h-pyrido(2,3-b)indol-9-yl)-p-tolyl]-n-((alpha.r)alpha(hydroxymethyl)benzyl)cyclopentaneacetamide
1,2,3-Dihydro-5-benzo(b)thienyl-2-(4-phenylbutylamino)-1-propanol

–7.499

–44.513

–7.463

–64.419

–7.407

–44.191

Quinidine

–7.380

–48.078

Tilisolol

–7.346

–24.419

Primozida

–7.341

–66.157

Ad 810

–7.340

–37.037

Carbuterol

–7.313

–18.889

Pronetalol

–7.293

–24.264

Vanyldisulfamide

–7.290

–61.900

Difebarbamate

–7.235

–76.184

Compounds
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Table. Continued.

Piroxicillin

Docking score Average MM/GBSA
(kcal/mol)
(kcal/mol)
–7.230
–57.173

Dapoxetine

–7.187

–49.660

Etanterol

–7.179

–12.707

Zinterol

–7.167

–42.080

Amosulalol

–7.145

–45.639

Fenprostalene

–7.136

–57.394

Carazolol

–7.128

–37.720

Benzquercin

–7.119

–96.802

Naftopidil

–7.113

–56.904

Denopamine

–7.107

–56.310

Brefonalol

–7.107

–44.698

Nardeterol

–7.106

–49.928

3-(Cis-2,6-dimethylpiperidino)-n-(4 methoxybenzoyl)sidnonimine

–7.095

–52.087

Nordefrin

–7.083

–28.408

Ametantrone

–7.079

–49.325

Epicainide

–7.078

–60.527

Carteolol

–7.077

–29.853

Cinacalcet

–7.058

–52.311

N-benzoyl-l-tyrosyl-paba

–7.034

–71.183

Panamesine

–7.013

–56.305

Neraminol

–7.005

–45.562

Bucindolol

–7.003

–60.390

Unii-f6s9cmy4se

–7.002

–63.674

Giripladib

–6.975

–64.455

Pancopride

–6.969

–52.768

Nolinium bromide

–6.962

–51.067

Compounds

and analyse MD simulations. Desmond was used in
all MD simulations. Table represents the average MM/
GBSA scores using the recorded 1000 frames (strided
by 10 during the simulations in each system) of the top50 ligands. In order to compare the docking scores and
average MM/GBSA scores of identified hit compounds
through our virtual screening protocol, we also used same
screening protocol for a well-known TMPRSS2 inhibitor,
Camostat mesylate. It is an approved small molecule
compound for the treatment of pancreatitis in Japan. It is
found that Camostat mesylate prevents SARS-CoV-2 cell
entry by inhibition of host serine protease TMPRSS2. Its
docking score was –5.444 kcal/mol at the binding pocket
of the TMPRSS2. Its corresponding average MM/GBSA
score was calculated as –65.514 kcal/mol. Figure S3 at the
Supplementary Materials shows 2D ligand interactions
diagram of Camostat mesylate at the binding site of
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SARS-CoV-2 TMPRSS2 target. Crucial residues were
found as Val280, Asp435, Ser436, Gln438, Gly439, Ser441,
Ser460, and Val473. Based on average MM/GBSA scores
of short MD simulations, we selected 3 hits that have
better scores than –70.0 kcal/mol, which are Benzquercin,
Difebarbamate, and N-benzoyl-l-tyrosyl-paba. Long (100ns) MD simulations were performed for these compounds
and MM/GBSA scores were recalculated. Results showed
that Benzquercin, N-benzoyl-l-tyrosyl-paba, and
Difebarbamate have average MM/GBSA scores of –80.583,
–56.162, and –66.567 kcal/mol, respectively. Results showed
that especially Benzquercin (a flavonoid) has maintained
the interactions with the binding pocket residues.
Although average MM/GBSA score of Difebarbamate is
slightly decreased at the long MD simulations compared
to short simulation, it has still similar range of MM/GBSA
score with positive control compound Camostat. Figure

Figure 2. (A) Surface representation of benzquercin at the binding pocket of TMPRSS2. The last frame from 100-ns MD simulations was used. (B) 3D ligand interactions
diagram of benzquercin at the TMPRSS2 site. (C) Corresponding interactions were also depicted with 2D. (D) Interaction fractions of binding pocket residues of TMPRSS2 with
benzquercin throughout the MD simulations. Results show statistical results of collected 1000-trajectory frames throughout 100-ns MD simulations.
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2 represents the 2D and 3D ligand interactions diagram
of Benzquercin at the binding site of TMPRSS2. The last
frame from 100-ns MD simulations was used. Crucial
residues at the target were found as His296, Glu299,
Pro301, Leu302, Lys340, Lys342, Gly439, and Ser441
which share similar binding pocket residues with positive
control Camostat. Based on interaction fractions analysis
Lys342 has the highest interaction fraction value with the
hit compound throughout the 100-ns simulations. The
type of main interactions between the ligand and binding
pocket residues were hydrogen bonds through water
bridges and hydrophobic interactions.
Interestingly, benzquercin was also found as potent hit
compounds in our previous virtual screening study
using same protocol against another important cellentry target of SARS-CoV-2 Spike/ACE2 (Durdagi et al.,
2020). Its average score at the Spike/ACE2 interface was
found as –70.810 kcal/mol. Hence, these studies showed
that benzquercin may also act as dual inhibitor. It has
been recognized that the treatment of “one target/one
molecule” approach of complex diseases is not so effective.
The usage of combined drugs is not also appreciated due
to toxicity and/or undesirable drug-drug interactions. The
recent and promising approach to these complex diseases
including COVID-19 is instead to develop/identify unique
compounds that act on multi-targets simultaneously
which these targets are crucial in the studied disease. Thus,
based on in silico results, benzquercin has this potential.

4. Conclusions
Molecular modeling studies, such as virtual screening,
reduce the time required to set new targets for known
drugs and also provide the advantage of being costeffective (Shoichet et al., 2002; Durdagi et al., 2018 and
2020). In this study, a virtual drug repurposing study was
performed to identify new compounds against TMPRSS2
which is an important target for the entry of the SARSCoV-2 to the host cell. Thus, NPC small molecule library
was screened initially by docking simulations. Based on
docking scores, top-50 compounds were used in short
MD simulations and their average binding free energies
were calculated by MM/GBSA method. Selected hits were
used in longer MD simulations and results showed that
especially benzquercin maintains its interactions with the
crucial residues throughout the simulations. If these results
can be validated by experimental studies, benzquercin can
be considered to be used as inhibitor of TMPRSS2 at the
clinical studies.
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Figure S1. Structural assessment of developed homology model structure of TMPRSS2. (A) Ramachandran’s plot. While filled spheres
show each chiral residue at the target protein, filled triangles show Gly residues. (B) Local quality estimate of the derived model. (C)
Normalized QMEAN4 score and its comparison with similar size of a set of PDB structures.
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Figure S2. Docking scores of all screened compounds at the binding pocket of TMPRSS2.
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Figure S3. 2D ligand interactions diagram of Camostat at the binding pocket of TMPRSS2.
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